8-K: Co-Diagnostics Reports Q2 2025 Financials Amid Platform Progress

Co-Diagnostics, Inc. announced its second quarter 2025 financial results, reporting a significant revenue decline but progress on its Co-Dx PCR platform clinical evaluations.

Summary

• Revenue for Q2 2025 was $0.2 million, a substantial decrease from $2.7 million in Q2 2024, primarily due to no grant revenue recognized in the current quarter.
• Operating expenses decreased by 19.1% to approximately $8.2 million in Q2 2025 compared to the prior year.
• Operating loss increased to $8.1 million in Q2 2025 from $7.7 million in Q2 2024.
• Net loss was $7.7 million, representing a loss of $0.23 per fully diluted share, compared to a net loss of $7.6 million, representing a loss of $0.25 per fully diluted share, in Q2 2024.
• Adjusted EBITDA loss increased to $7.2 million from $5.9 million in Q2 2024.
• Cash, cash equivalents, and marketable securities stood at $13.4 million as of June 30, 2025.
• The company remains on track to initiate clinical evaluations for all tests in its Co-Dx PCR platform pipeline before year-end.
• Training of clinical evaluation sites for the enhanced COVID-19 test is underway, with trial participant acceptance expected imminently.

Sentiment

Score: 3

Explanation: The financial results show significant declines in revenue and increased losses, indicating poor performance. While there is positive progress on product development and clinical trials, the current financial state is concerning, especially the substantial reduction in marketable securities and total current assets. The positive outlook on future product commercialization is offset by the immediate financial challenges.

Positives

• Operating expenses decreased by 19.1% to $8.2 million in Q2 2025 compared to Q2 2024.
• Loss per fully diluted share improved to $0.23 in Q2 2025 from $0.25 in Q2 2024, despite a higher net loss, indicating share count management or other factors.
• The company remains on track to initiate clinical evaluations for all tests in its Co-Dx PCR platform pipeline before year-end 2025.
• Training for clinical evaluation sites for the enhanced COVID-19 test is in progress, with trial participants expected imminently.
• Cash and cash equivalents increased significantly to $11,115,181 as of June 30, 2025, from $2,936,544 as of December 31, 2024.

Negatives

• Total revenue declined significantly to $0.2 million in Q2 2025 from $2.7 million in Q2 2024, primarily due to the absence of grant revenue.
• Operating loss increased to $8.1 million in Q2 2025 from $7.7 million in Q2 2024.
• Net loss increased to $7.7 million in Q2 2025 from $7.6 million in Q2 2024.
• Adjusted EBITDA loss increased to $7.2 million in Q2 2025 from $5.9 million in Q2 2024.
• Total current assets decreased substantially to $15,307,166 as of June 30, 2025, from $32,291,698 as of December 31, 2024, largely due to a reduction in marketable investment securities.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances.
• Actual results may differ materially from those contemplated or anticipated by forward-looking statements.
• There is no assurance that any anticipated results will occur on a timely basis or at all.

Future Outlook

The company expects to initiate clinical evaluations for all tests in its Co-Dx PCR platform pipeline before year-end 2025, with the enhanced COVID-19 test being the first of four infectious disease PCR test panels planned for regulatory submission. Management believes the platform will be crucial in transforming global diagnostic testing accessibility and is confident in achieving nearand long-term commercialization goals.

Management Comments

• The investments made during the course of developing the Co-Dx PCR platform from the ground-up have all contributed to the robust manufacturing, development, and regulatory framework required to successfully bring it to market, and we are pleased to report that we remain on track to reach our 2025 development and regulatory milestones.
• The enhanced COVID-19 test is planned to be the first of four infectious disease PCR test panels submitted for regulatory clearance following completion of the clinical evaluations.
• We are confident in the quality of our real-time PCR point-of-care platform and believe that the results of our clinical evaluations will position us for strong regulatory submissions in multiple jurisdictions, as we move closer to our nearand long-term commercialization goals.

Industry Context

The molecular diagnostics industry continues to evolve with a focus on point-of-care and at-home testing solutions. Co-Diagnostics' emphasis on its Co-Dx PCR platform, including an enhanced COVID-19 test and other infectious disease panels, aligns with this trend, aiming to increase accessibility to diagnostic testing. The significant decline in grant revenue may reflect a broader shift in funding priorities post-pandemic, requiring companies to rely more on product sales and commercialization efforts.

Stakeholder Impact

• Shareholders: Negative impact due to increased net loss, significant revenue decline, and reduction in total current assets. Potential positive impact from future product commercialization if clinical trials are successful.
• Employees: Continued investment in R&D and platform development suggests ongoing work, but financial performance could raise concerns about long-term stability.
• Customers: Potential benefit from new diagnostic tests becoming available, especially point-of-care and at-home solutions.
• Creditors: Reduced current assets and ongoing losses could increase perceived credit risk.

Next Steps

• Initiate clinical evaluations for all tests in the Co-Dx PCR platform pipeline before year-end 2025.
• Begin accepting trial participants for the enhanced COVID-19 test imminently.
• Submit the enhanced COVID-19 test for regulatory clearance following clinical evaluations.
• Submit three additional infectious disease PCR test panels for regulatory clearance.
• Move towards nearand long-term commercialization goals for the Co-Dx PCR platform.
• Host a conference call and webcast on August 14, 2025, to discuss financial results.

Key Dates

Recommendation

The company reported a substantial decline in revenue, primarily due to the absence of grant revenue, and increased operating and net losses. While operating expenses decreased, the overall financial performance for Q2 2025 is significantly worse than the prior year. The substantial reduction in marketable investment securities and total current assets raises concerns about liquidity and cash burn. Although there is progress on clinical evaluations for the Co-Dx PCR platform, the current financial deterioration outweighs the future potential, suggesting a 'sell' recommendation for investors given the immediate negative financial indicators and increased risk profile.

Keywords

Co-Diagnostics, CODX, Molecular Diagnostics, PCR Platform, Financial Results, Q2 2025, Earnings, COVID-19 Test, Clinical Evaluations, Regulatory Milestones, Point-of-Care Diagnostics, Biotechnology